Zimmer Biomet/$ZBH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Zimmer Biomet
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
Ticker
$ZBH
Sector
Primary listing
NYSE
Industry
Health Care Equipment & Supplies
Headquarters
Employees
17,000
ISIN
US98956P1021
Website
Zimmer Biomet Metrics
BasicAdvanced
$18B
20.09
$4.51
0.78
$0.96
1.06%
Price and volume
Market cap
$18B
Beta
0.78
52-week high
$116.37
52-week low
$89.22
Average daily volume
2.2M
Dividend rate
$0.96
Financial strength
Current ratio
2.436
Quick ratio
1.271
Long term debt to equity
53.018
Total debt to equity
59.058
Dividend payout ratio (TTM)
21.28%
Interest coverage (TTM)
6.61%
Profitability
EBITDA (TTM)
2,555.1
Gross margin (TTM)
71.20%
Net profit margin (TTM)
11.86%
Operating margin (TTM)
20.03%
Effective tax rate (TTM)
12.91%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
4.42%
Return on equity (TTM)
7.32%
Valuation
Price to earnings (TTM)
20.088
Price to revenue (TTM)
2.37
Price to book
1.45
Price to tangible book (TTM)
-16.88
Price to free cash flow (TTM)
16.137
Free cash flow yield (TTM)
6.20%
Free cash flow per share (TTM)
561.12%
Dividend yield (TTM)
1.06%
Forward dividend yield
1.06%
Growth
Revenue change (TTM)
3.30%
Earnings per share change (TTM)
-2.33%
3-year revenue growth (CAGR)
3.77%
10-year revenue growth (CAGR)
5.18%
3-year earnings per share growth (CAGR)
62.92%
10-year earnings per share growth (CAGR)
1.46%
10-year dividend per share growth (CAGR)
0.87%
What the Analysts think about Zimmer Biomet
Analyst ratings (Buy, Hold, Sell) for Zimmer Biomet stock.
Bulls say / Bears say
Zimmer Biomet's acquisition of Paragon 28 for $1.1 billion is expected to expand its portfolio in orthopedic surgical devices, potentially driving future revenue growth. (reuters.com)
The company reported stronger-than-expected first-quarter results, with adjusted earnings of $1.81 per share on $1.91 billion in revenue, indicating robust demand for its hip and knee devices. (reuters.com)
Zimmer Biomet's issuance of $700 million in notes due 2034 provides additional capital, potentially supporting strategic initiatives and growth opportunities. (investing.com)
Zimmer Biomet lowered its 2025 full-year adjusted profit forecast, citing anticipated financial impacts from the Paragon 28 acquisition, proposed U.S. tariffs, and currency fluctuations. (reuters.com)
The company reduced its 2024 profit outlook due to expected ERP disruptions in the second half of the year, leading to a downward revision of earnings forecasts. (investing.com)
Despite better-than-expected Q4 2024 results, Zimmer Biomet's stock declined after setting its 2025 outlook below consensus estimates, raising concerns about future performance. (seekingalpha.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jun 2025.
Zimmer Biomet Financial Performance
Revenues and expenses
Zimmer Biomet Earnings Performance
Company profitability
Zimmer Biomet News
AllArticlesVideos
We pay attention to policy and patients, says Zimmer Biomet CEO Ivan Tornos
CNBC Television·1 month ago
Stifel Has Big Second-Half Stock Market Concerns: 5 Defensive Value Dividend Stocks Buys
24/7 Wall Street·1 month ago
These Analysts Lower Their Forecasts On Zimmer Biomet After Q1 Results
Benzinga·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Jun26
Zimmer Biomet
Dividend·Ex-dividend
Jul31
Zimmer Biomet
Dividend·Payment
$0.24Per share
FAQs
What’s the current market cap for Zimmer Biomet stock?
Zimmer Biomet (ZBH) has a market cap of $18B as of June 20, 2025.
What is the P/E ratio for Zimmer Biomet stock?
The price to earnings (P/E) ratio for Zimmer Biomet (ZBH) stock is 20.09 as of June 20, 2025.
Does Zimmer Biomet stock pay dividends?
Yes, the Zimmer Biomet (ZBH) stock pays dividends to shareholders. As of June 20, 2025, the dividend rate is $0.96 and the yield is 1.06%. Zimmer Biomet has a payout ratio of 21.28% on a trailing twelve-month basis.
When is the next Zimmer Biomet dividend payment date?
The next Zimmer Biomet (ZBH) dividend payment is scheduled for July 31, 2025.
What is the beta indicator for Zimmer Biomet?
Zimmer Biomet (ZBH) has a beta rating of 0.78. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.